With deep ties to Bay­lor and fresh sup­port from Po­laris, Sin­ga­pore's Tes­sa rais­es $126M for piv­otal CAR study

Tes­sa Ther­a­peu­tics in Sin­ga­pore has been through mul­ti­ple rais­es over the last decade for its cell ther­a­py R&D work. But with US-based VC Po­laris step­ping in to lead the new $126 mil­lion round as it sits on the thresh­old of a piv­otal ex­pe­di­tion in the clin­ic fo­cused on the US and Eu­rope, they’re call­ing this new one to­day a Se­ries A.

Go fig­ure.

That fresh raise comes on top of the more than $200 mil­lion al­ready gar­nered for its work, in­ter­im CEO John Ng tells me. Temasek, the $283 bil­lion sov­er­eign wealth fund in Sin­ga­pore that’s played a ma­jor role in build­ing the coun­try’s tech in­dus­try, has been a key play­er here. ED­BI, He­li­co­nia Cap­i­tal and Her­i­tas Cap­i­tal al­so fig­ure in as ex­ist­ing in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER